11641

Excision of Malignant Lesion, Face/Ears/Eyelids/Nose/Lips, 0.6 to 1.0 cm

CPT 11641 describes the surgical excision of a malignant skin lesion located on the face, ears, eyelids, nose, or lips, where the total excised diameter (including the lesion and the necessary margins) is between 0.6 cm and 1.0 cm. This procedure is distinct from benign excision because of the clinical nature of the lesion and the depth/breadth of margins required to ensure oncology clearance. The physician begins by identifying the boundaries of the malignancy and marking out the narrowest clinical margins necessary for complete removal, which for these critical anatomical sites must balance oncological safety with cosmetic preservation. The measurement used for code selection is the widest diameter of the lesion plus the narrowest margins required at each side. After the area is prepped and anesthetized with local anesthetic, the physician performs a full-thickness excision through the dermis and potentially into the subcutaneous fat. The specimen is removed and typically oriented for pathology to ensure all margins are clear of malignant cells. Hemostasis is achieved through electrocautery or pressure. This code specifically includes simple (non-layered) closure of the resulting wound. If the defect requires an intermediate or complex closure, those services are reported separately. Because the face, ears, nose, and lips are high-visibility and functionally sensitive areas, the surgical approach requires significant precision to minimize scarring and prevent structural distortion. Documentation must clearly state the lesion's malignancy (either via prior biopsy or clinical assessment) and the specific measurements taken before the excision.

Clinical Indications

  • Biopsy-proven Basal Cell Carcinoma (BCC) of the face, nose, or ears.
  • Biopsy-proven Squamous Cell Carcinoma (SCC) of the lips or eyelids.
  • Clinical diagnosis of a malignant melanoma in situ in the facial region.
  • Suspicious lesion in a high-risk anatomical site (nose, ear, lip) with clinical features strongly suggestive of malignancy.
  • Recurrent malignant skin lesions in the designated anatomical areas.
  • Other malignant skin neoplasms such as Merkel cell carcinoma or sebaceous gland carcinoma.

Procedure Steps

  1. Identification and marking of the lesion boundaries.
  2. Measurement of the lesion's widest diameter.
  3. Marking of the narrowest margins required for clinical clearance (e.g., 2-4mm).
  4. Calculation of the total excised diameter (widest lesion diameter + 2x margin width).
  5. Application of local anesthesia (e.g., lidocaine with epinephrine).
  6. Full-thickness skin excision down to the subcutaneous fat layer.
  7. Removal of the specimen and orientation for pathological examination.
  8. Achieving hemostasis using electrocoagulation or ligation.
  9. Simple, single-layer closure of the wound (included in the code).
  10. Application of sterile dressing and post-operative instructions.

Coding Guidelines

  • Code selection is based on the anatomical site and the excised diameter (lesion + margins), not the size of the resulting defect.
  • The diameter is measured before the excision; do not use the size of the specimen after it has been placed in formaldehyde, as tissue shrinks.
  • Malignant excision codes include simple closure. If intermediate (12031-12057) or complex (13131-13153) repair is required, it should be reported separately.
  • If multiple lesions are excised, report each separately using the appropriate CPT code and modifier 59 or XS.
  • For excision of a malignant lesion followed by a skin graft or flap, the excision is bundled into the flap/graft code if the flap/graft code description includes excision (e.g., 14040), but typically for 11641, the excision is reported and the flap/graft (like 15004) is reported as well depending on specific NCCI edits.
  • Do not use 11641 for Mohs Micrographic Surgery (17311-17315).

Associated ICD-10 Codes